Here are the 424B prospectus supplements from Azitra Inc (AZTR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow AZTR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AZTR filings page.
Azitra, Inc. may offer and sell common stock with an aggregate offering price of up to $3,503,232 under an at-the-market sales agreement with A.G.P./Alliance Global Partners, acting as agent or principal. Sales may occur from time to time, subject to the agreement’s conditions. A.G.P. is entitled to a cash fee equal to 3.0% of gross proceeds, and Azitra intends to use net proceeds for working capital and general corporate purposes.
Azitra’s public float was approximately $10,509,696 as of September 25, 2026. While it remains below $75 million, Form S-3 limits public primary sales to no more than one-third of public float in any 12-month period. As of June 30, 2026, total assets were $8.9 million and working capital was $5.9 million; Azitra said cash on hand plus offering proceeds would not cover its proposed operations for at least the next 12 months. The incorporated audit report describes conditions that raise substantial doubt about Azitra’s ability to continue as a going concern.
Azitra paused ATR-12 trial enrollment in June 2026 for capital preservation. It continues IND-enabling studies for ATR-01 and plans to announce initial ATR-04 Cohort 1 data around Q4 2026.
Azitra, Inc. is registering up to 51,812,293 shares of common stock for resale by Alumni Capital and other selling stockholders under a November 2025 private placement and an existing equity line of credit (ELOC). The shares include stock already issued plus shares underlying pre-funded warrants, common stock purchase warrants, placement agent warrants and ELOC warrants. Azitra will not receive proceeds from stockholder resales but may receive up to about $1.57 million from cash exercise of November warrants and about $14.0 million from additional ELOC share sales, on top of $6.0 million previously raised, plus potential warrant exercise proceeds. Common stock outstanding was 10,740,697 shares as of December 15, 2025 and could rise to 62,552,990 shares if all related warrants are exercised. The company is an early-stage dermatology biotech with three lead engineered-microbe programs and faces significant financing needs, NYSE American equity deficiency issues and substantial dilution risk from these facilities.